Navigation Links
Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary

BELLEVILLE, ON, July 10 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, presented data regarding its E. coli O157:H7 cattle vaccine at the XXV World Buiatrics Congress in Budapest, Hungary today. The presentation was made by Dr. Dragan Rogan, Vice-President, Bioniche Animal Health Research & Development. It was entitled, "Vaccination of Cattle with E. coli O157:H7 Type III Secretion Proteins as a Pre-Slaughter Intervention Method to Reduce E. coli O157:H7 Prevalence", and was co-authored by Dr. David Smith, Dr. Rod Moxley, Dr. Andy Potter and Julie Yome.

The World Buiatrics Congress is the largest event of its kind in the cattle industry, and is attended by scientists from universities and research institutes, practitioners working with dairy and beef cattle and other ruminants, consultants, post-docs, PhDs and graduate students of veterinary medicine and animal science from around the world.

The Bioniche vaccine is the world's first vaccine that may be used as an on-farm intervention to reduce the amount of E. coli O157:H7 shed by cattle. Bioniche and its collaborators have been moving the vaccine towards commercial availability for eight years and it has been extensively tested at the University Nebraska-Lincoln, with efficacy results now being published in peer-reviewed scientific journals, most recently, the Journal of Food Protection, in November, 2007.

In his presentation in Budapest, Dr. Rogan summarized numerous studies that have been completed with the Bioniche vaccine over the last five years involving more than 30,000 cattle. In one study, calves were vaccinated with three doses and challenged with E. coli O157:H7 14 days later. There was a 2.28 log10 reduction in the magnitude of shedding in vaccinated animals compared to controls. In another study, with a three-dose vaccination and natural exposure to E. coli O157:H7, vaccinated animals were less likely to be colonized by the bacteria in the mucosa of the terminal rectum at harvest (OR=0.014, p<0.0001), resulting in a vaccine colonization efficacy of 98.3%. A two-dose vaccination was used to evaluate hide contamination in the feedlot. Hides were sampled for E. coli O157:H7 contamination twice in the feedlot and immediately before and after animals were shipped to the abattoir. This same study also found a statistically significant reduction in the likelihood of vaccinated animals having contaminated hides. Additionally, pen-level prevalence following a two dose vaccination was assessed in a feedlot study. Vaccinated pens were less likely than unvaccinated pens to test positive (OR=0.59, p<0.004) using the ROPES method.

"These results provide compelling evidence that vaccination of cattle with the Bioniche E. coli O157:H7 cattle vaccine has the potential to be an effective pre-slaughter intervention for the reduction of E. coli O157:H7 shedding, colonization, hide contamination, and pen-level prevalence," concluded Dr. Rogan.

Food recalls due to E. coli O157:H7 contamination continue to be a concern in beef, produce and prepared food. On-farm interventions to reduce the shedding of E. coli O157:H7 by cattle, such as vaccination, may assist in reducing the potential for food and water contamination and the resulting human illnesses and deaths.

Approximately 100,000 cases of human infection with the E. coli O157:H7 organism are reported each year in North America. 2% to 7% of those people develop hemolytic uremic syndrome (HUS), a disease characterized by kidney failure (in recent outbreaks, this percentage has risen to as high as 16%). Five percent of HUS patients die, many of them children and senior citizens, whose kidneys are more sensitive to damage.

In addition to being infected by contaminated food or water, individuals can become infected from E. coli O157:H7 by visiting animal exhibits. Petting zoos, fairs, and agricultural exhibits provide many possible routes of transmission for E. coli. Direct animal contact is the obvious route, but contact with contaminated products (e.g., sawdust, shavings, soiled clothing or shoes) can also lead to human infection.

The E. coli O157:H7 cattle vaccine will be manufactured in the Bioniche production facility in Belleville, Ontario, Canada where a two-year, $25 million expansion is taking place, supported by the Ontario and Canadian governments. Vaccine supply will be limited during this manufacturing expansion period.

About the E. coli O157:H7 Cattle Vaccine

This vaccine received international recognition in September, 2007 by the Animal Pharm Industry Excellence Awards as the best new veterinary product for livestock globally. The vaccine has been developed by a strategic alliance formed in 2000 between the University of British Columbia (UBC), the Alberta Research Council (ARC), the University of Saskatchewan's Vaccine & Infectious Disease Organization (VIDO), and Bioniche, which holds the rights for worldwide commercialization of the vaccine. The vaccine prevents the E. coli O157:H7 bacteria from attaching to the intestines of vaccinated cattle, thereby reducing their reproduction within the animal, and reducing the amount of bacteria that can be released through cattle manure in the environment. More than 30,000 cattle have been involved in clinical testing of the vaccine over the past five years.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of Canada's Top Ten Life Sciences Companies for 2008. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
2. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
3. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
6. Bioniche Reports Fiscal 2008 Third Quarter
7. Bioniche Appoints U.S. President of Food Safety
8. Bioniche Reports the Passing of its Board Chair
9. Bioniche Converts a Portion of its Debt to Equity
10. Bioniche Receives Fast Track Designation For First-Line Bladder Cancer Therapy
11. Bioniche Pharma Chooses TrackWise for its Deviation Control Solution
Post Your Comments:
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... be a safe and convenient way to dispense prescription medications at home, so ... and effective way to monitor and dispense prescription medications. In doing so, it ...
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Japanese therapeutic drug monitoring market, ...
Breaking Medicine Technology: